Pittsburgh – September 29, 2026 -- Viatris Inc. (Nasdaq: VTRS) has been named to Forbes' World's Best Employers list for the sixth consecutive year, based on an independent survey of more than 300,000 employees across over 50 countries.

Columbia, Md. – September 29, 2026 -- The Maryland Stem Cell Research Commission has awarded more than $4.8 million through the Maryland Stem Cell Research Fund (MSCRF) in the first funding cycle of fiscal year 2027, backing 15 investigators across the state's regenerative medicine sector.

Dallas – – September 29, 2026 -- MassChallenge, ranked the No. 2 accelerator in the U.S. by TIME and Statista, has named Dallas its second U.S. headquarters, backed by a renewed two-year grant from Lyda Hill Philanthropies. The investment extends a five-year partnership at Pegasus Park and will fund two ten-week accelerator tracks in Health & Life Sciences and Security & Resiliency, plus Founder Access Clinics connecting early-stage founders with academic, clinical and corporate stakeholders.

Milwaukee – September 29, 2026 -- PBS Biotech has embedded Rockwell Automation technology into its MiniPRO multi-parallel bioreactor platform, a system with up to 24 independently controlled bioreactors designed to speed cell therapy process development and reduce risk during scale-up to commercial manufacturing.

New York City – – September 29, 2026 -- Demy-Colton has released the agenda for BioFuture 2026, a two-day conference set for October 27–28 at Cure, 345 Park Avenue South, drawing more than 100 speakers and over 50 presenting companies from biopharma, investment, technology and policy sectors.

Staten Island, N.Y. – September 29, 2026 -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) has enrolled the first patient in its PATHFINDER clinical trial evaluating ibezapolstat in patients with multiply-recurrent Clostridioides difficile infection (rCDI), a condition affecting up to 40% of patients treated with vancomycin after multiple prior episodes.

Indianapolis – September 29, 2026 -- Eli Lilly and Company said a new indirect treatment comparison shows Zepbound (tirzepatide) 15 mg produced 4.5% greater body-weight loss than Novo Nordisk's Wegovy HD (semaglutide 7.2 mg) in adults with obesity, intensifying the competitive battle in the obesity-drug market. The 10 mg dose of Zepbound delivered 3.2% greater weight reduction than Wegovy HD, according to data presented at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan.

Calgary – September 29, 2026 -- Providence Therapeutics Holdings, Inc. has formed its first Clinical Advisory Board to guide development of its therapeutic mRNA cancer vaccine programs, including a personalized vaccine for pediatric brain cancer and off-the-shelf precision therapies for solid tumors.

Chief Medical Officer Leon Rozen chairs new four-member advisory panel

Dr. Rozen leads the board, which brings in Ezra Cohen, MD; Melinda Merchant, MD, PhD; and John Powderly, MD, to steer clinical strategy for the company's cancer vaccine pipeline.

Plainsboro, N.J. – – September 29, 2026 -- Novo Nordisk reported that adults with type 2 diabetes who escalated their semaglutide dose to 2 mg showed a statistically significant 6% lower risk of major adverse cardiovascular events (MACE) compared with patients who switched to tirzepatide, according to real-world data presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026 in Milan.

Washington, D.C. – September 29, 2026 -- LUNGevity Foundation has committed $2 million to fund two three-year clinical research projects aimed at improving the diagnosis of indeterminate pulmonary nodules (IPNs), a condition affecting more than 1.5 million Americans annually after routine chest CT scans.